溶血性链球菌制剂OK432联合肿瘤冻融抗原诱导小鼠骨髓树突状细胞的成熟  

Combined OK432 and Freeze-thawed Tumor Cell Antigen in Maturation of Dendritic Cells from Mouse Bone Marrow

作　　者：曾真[1] 倪秀雄[1] 袁明洲[1] 

机构地区：[1]福建医科大学基础医学院生理学与病理生理学系,福州350004

出　　处：《福建医科大学学报》2008年第5期396-399,407,共5页Journal of Fujian Medical University

基　　金：福建省自然科学基金资助项目(C0410020)

摘　　要：目的探讨溶血性链球菌制剂(OK432)联合肿瘤冻融抗原诱导小鼠骨髓树突状细胞(DCs)成熟的作用,改进体外诱导DCs成熟的方案,为后期制备临床使用的抗肿瘤DCs疫苗提供新的技术路线。方法分离小鼠骨髓单核细胞(BMMCs),并在含10%胎牛血清(FCS)、重组小鼠粒-巨噬细胞集落刺激因子(rmGM-CSF)、重组小鼠白细胞介素-4(rmIL-4)的培养体系中诱导培养,部分加入OK432和/或肿瘤冻融抗原冲击,光镜和透射电镜下观察细胞形态,流式细胞仪检测细胞表面分子CD83和CD86的表达情况。结果经OK432联合肿瘤细胞冻融抗原冲击的DCs形态学特征典型。肿瘤冻融抗原冲击后,DCs表面CD83和CD86的表达上调,OK432进一步刺激后,CD83和CD86的表达率显著升高。结论采用OK432联合肿瘤冻融抗原诱导DCs成熟的方案相对简便;OK432能有效促进肿瘤冻融抗原冲击后的骨髓DCs进一步成熟。Objective To investigate the effect of OK432 and freeze-thawed tumor cell antigen in maturation of dendritic cells（DCs） from mouse bone marrow, and improve the means of maturation of den- dritic cells in vitro so as to offer a new technical way of preparation DCs-based vaccines for the cancer im- munotherapy. Methods Mouse bone marrow mononuclear cells （BMMCs） were cultured in RPMI1640 containing 10% FCS,rmGM-CSF and rmlL-4, pulsed with OK432 and /or freeze-thawed tumor cell anti- gen. Morphological characters of DCs were observed by the optical microscope and the electron micro- scope; DCs surface molecules CD83 and CD86 were assayed by flow cytometry. Results Induced by OK432 and freeze-thawed tumor cell antigen, DCs showed morphologically typical characters. And they expressed much more antigens CD83 and CD86 on the surface after cultured0by pulsed with freeze-thawed tumor cell antigen. Notably more antigens CD83 and CD86 were detected on the surface of DCs which were pulsed with both of OK432 anf freeze-thawed tumor cell antigen. Oonclusion It was simple and practicable to induce maturation of DCs by OK432 and freeze-thawed tumor cell antigen. OK432 could markedly enhanced the maturity of DCs which had been pulsed with freeze-thawed tumor cell antigen.

关 键 词：树突细胞 溶血性链球菌制剂 骨髓 抗原 肿瘤 

分 类 号：R392[医药卫生—免疫学] R730.5[医药卫生—基础医学]